Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Stock Information for Inseego Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inseego Corp.

INOVIO to Participate in December Investor Conferences
INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Announces Proposed Public Offering
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.